{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:38:48Z","timestamp":1787503128050,"version":"build-2736575974"},"reference-count":93,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2008,5,7]],"date-time":"2008-05-07T00:00:00Z","timestamp":1210118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2008,8]]},"abstract":"<jats:p>\n                    <jats:bold>BACKGROUND:<\/jats:bold>\n                    Plasma fractionators have implemented many improvements over the past decade directed toward reducing the likelihood of pathogen transmission by purified blood products, yet little has been published attempting to assess the overall impact of these improvements on the probability of safety of the final product.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>STUDY DESIGN AND METHODS:<\/jats:bold>\n                    Safety margins for human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), hepatitis A virus (HAV), parvovirus B19, and variant form of Creutzfeldt\u2010Jakob disease (vCJD) were calculated for the two fibrin sealants licensed in the United States and for thrombin. These products were selected because their use in a clinical setting is, in most cases, optional, and both were relatively recently approved for marketing by the US Food and Drug Administration (FDA). Moreover, thrombin and fibrinogen both undergo two dedicated virus inactivation steps and\/or removal steps in accord with the recommendations of regulatory agencies worldwide. Safety margins were determined by comparing the potential maximum viral loads in contaminated units to viral clearance factors, ultimately leading to the calculation of the residual risk per vial.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>RESULTS:<\/jats:bold>\n                    The residual risk of pathogen transmission per vial was calculated to be less than 1 in 10\n                    <jats:sup>\u221215<\/jats:sup>\n                    for HIV, HCV, HBV, and HAV for both fibrinogen and thrombin. Owing to the greater quantities that can be present and its greater thermal stability, the calculated risk for parvovirus transmission was 1 in 500,000 vials for fibrinogen and less than 1 in 10\n                    <jats:sup>7<\/jats:sup>\n                    per vial for thrombin. Assuming that vCJD is found to be present in plasma donations, its risk of transmission by these purified and processed plasma derivatives would appear to be very low.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>CONCLUSIONS:<\/jats:bold>\n                    The pathogen safety initiatives implemented by plasma fractionators over the past 10 to 20 years have resulted in products with excellent pathogen safety profiles. Of the agents examined, parvovirus continues to have the lowest calculated margin of safety. Despite this, parvovirus transmissions should be rare. Manufacturers are encouraged to continue exploring processes to further enlarge parvovirus safety margins and to continue exploring ways of eliminating prions.\n                  <\/jats:p>","DOI":"10.1111\/j.1537-2995.2008.01717.x","type":"journal-article","created":{"date-parts":[[2008,5,7]],"date-time":"2008-05-07T13:30:22Z","timestamp":1210167022000},"page":"1739-1753","source":"Crossref","is-referenced-by-count":76,"title":["Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin"],"prefix":"10.1111","volume":"48","author":[{"given":"Bernard","family":"Horowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Busch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,7,29]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61199-4"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcp.0000208452.57854.c6"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1385\/CRIAI:29:3:167"},{"key":"e_1_2_6_5_2","first-page":"79","article-title":"Intravenous immunoglobulin and Alzheimer's disease immunotherapy","volume":"9","author":"Solomon B","year":"2007","journal-title":"Curr Opin Mol Ther"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2007.00901.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-475X.2003.11112.x"},{"key":"e_1_2_6_8_2","first-page":"543","article-title":"Large\u2010scale preparation of highly purified human C1\u2010inhibitor for therapeutic use","volume":"5","author":"Poulle M","year":"1994","journal-title":"Blood Coagul Fibrinolysis"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9610(01)00770-X"},{"key":"e_1_2_6_10_2","first-page":"887","article-title":"Risk and clinical significance of developing antibodies induced by topical thrombin preparations","volume":"122","author":"Dorion RP","year":"1998","journal-title":"Arch Pathol Lab Med"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-200101000-00014"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63043-X"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1067\/mlc.2002.123950"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00011.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2003.09.110"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2006.08.028"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-5956-3-1"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1089\/jir.1993.13.121"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/81.7.531"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1089\/hyb.1994.13.485"},{"key":"e_1_2_6_21_2","unstructured":"US Food and Drug Administration.Guidance for industry: Q5A viral safety evaluation of biotechnology products derived from cell lines of human or animal origin.September 1998. Available from: URL:http:\/\/www.fda.gov\/cder\/guidance\/q5a\u2010fnl.pdf"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199606273342601"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00174.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01493.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01365.x"},{"key":"e_1_2_6_26_2","first-page":"361","article-title":"Blood protein derivative viral safety: observations and analysis","volume":"63","author":"Horowitz B","year":"1990","journal-title":"Yale J Biol Med"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2006.00833.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tracli.2006.11.001"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1086\/429414"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1086\/429411"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3281532c82"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200309050-00005"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1159\/000076643"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044029"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2005.04390.x"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01234.x"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01276.x"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01522.x"},{"issue":"9","key":"e_1_2_6_39_2","first-page":"17A","article-title":"Infectivity of donations from eclipse and ramp\u2010up stages of HCV in chimpanzees. Abstract S39\u2010030H. Amer Assn of Blood Banks Annual Meeting 2007, Anaheim, CA., Oct 2007","volume":"47","author":"Busch MP","year":"2007","journal-title":"Transfusion"},{"issue":"9","key":"e_1_2_6_40_2","first-page":"17A","article-title":"Transmission of simian immunodeficiency virus (SIV) by plasma collected prior to detectable viremia, and infectivity of ramp\u2010up versus chronic stages. Abstract S40\u2010030H. Amer Assn of Blood Banks Annual Meeting 2007, Anaheim, CA, Oct 2007","volume":"47","author":"Ma M","year":"2007","journal-title":"Transfusion"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.67.4.1953-1958.1993"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1983.tb01906.x"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.18.6944"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2004.00505.x"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05411-3"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15486-X"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16811-6"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69835-8"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0041-1132.2003.00586.x"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2003.00280.x"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2005.00710.x"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01205.x"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1159\/000416564"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(94)00532-A"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890430109"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01703243"},{"key":"e_1_2_6_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1960.tb40943.x"},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1986.tb01962.x"},{"key":"e_1_2_6_59_2","first-page":"43","article-title":"Specific inactivation of viruses which can potentially contaminate blood products","volume":"75","author":"Horowitz B","year":"1991","journal-title":"Dev Biol Stand"},{"key":"e_1_2_6_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0967-2109(03)00068-1"},{"key":"e_1_2_6_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(02)03415-X"},{"key":"e_1_2_6_62_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2001.41010130.x"},{"key":"e_1_2_6_63_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01235.x"},{"key":"e_1_2_6_64_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3148.1999.009001003.x"},{"key":"e_1_2_6_65_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2002.00211.x"},{"key":"e_1_2_6_66_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0042-9007.2004.00403.x"},{"key":"e_1_2_6_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-3886(00)00011-4"},{"key":"e_1_2_6_68_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2000.7820086.x"},{"key":"e_1_2_6_69_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00617.x"},{"key":"e_1_2_6_70_2","first-page":"188","volume-title":"Creutzfeldt\u2010Jakob disease: managing the risk of transmission by blood, plasma, and tissues.","author":"Foster PR","year":"2006"},{"key":"e_1_2_6_71_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1999.39111160.x"},{"key":"e_1_2_6_72_2","doi-asserted-by":"publisher","DOI":"10.3109\/07853890009002023"},{"key":"e_1_2_6_73_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2005.04387.x"},{"key":"e_1_2_6_74_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2001.00120.x"},{"key":"e_1_2_6_75_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00158.x"},{"key":"e_1_2_6_76_2","unstructured":"CJD Incidents Panel.Fourth Annual Report 1st September 2003 to 31st August 2004 to the Advisory Committee on Dangerous Pathogens Working Group on Transmissible Spongiform Encephalopathies. Available from:http:\/\/www.hpa.nhs.uk\/infections\/topics_az\/cjd\/report03\u201004.pdf"},{"key":"e_1_2_6_77_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00129.x"},{"key":"e_1_2_6_78_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040085"},{"key":"e_1_2_6_79_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2005.00636_1.x"},{"key":"e_1_2_6_80_2","unstructured":"SchreiberGB GlynnSA ZerlauthG WrightDJ McEntireR.Estimated HIV HCV and HBV residual risks of source\u2010plasma starting material for plasma derived medicinal products.Vox Sang2008(in press)."},{"key":"e_1_2_6_81_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2007.00765.x"},{"key":"e_1_2_6_82_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01443.x"},{"key":"e_1_2_6_83_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2004.04215.x"},{"key":"e_1_2_6_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(06)80005-3"},{"key":"e_1_2_6_85_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.00524.x"},{"key":"e_1_2_6_86_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00974.x"},{"key":"e_1_2_6_87_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01503.x"},{"key":"e_1_2_6_88_2","first-page":"451a","article-title":"Phase IV study of Plas+SD: hepatitis A (HAV) and parvovirus B19 safety results","volume":"96","author":"Davenport R","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_89_2","doi-asserted-by":"publisher","DOI":"10.1086\/505226"},{"key":"e_1_2_6_90_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2004.00530.x"},{"key":"e_1_2_6_91_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.00496.x"},{"key":"e_1_2_6_92_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01135.x"},{"key":"e_1_2_6_93_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2004.00577.x"},{"key":"e_1_2_6_94_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1994.tb01246.x"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2008.01717.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2008.01717.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T04:54:07Z","timestamp":1697259247000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2008.01717.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,29]]},"references-count":93,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["10.1111\/j.1537-2995.2008.01717.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2008.01717.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,29]]}}}